Record ID: MS-N068 · Family: Supportive physical care / neuropathy prevention · Clinical question: Do frozen gloves and socks prevent clinically meaningful peripheral neuropathy during paclitaxel or docetaxel treatment?
Evidence label: Primary endpoint negative in a 2026 randomized trial; secondary sensory signals do not establish prevention.
Evidence at a glance
- Benefit: The CryoPac trial did not significantly reduce its prespecified primary neuropathy outcome, although some secondary sensory measures favored cooling.
- Certainty: Moderate for no demonstrated primary-endpoint benefit in this protocol; uncertainty remains because adherence was only 67%.
- Risk: Cold pain, intolerance and potential skin injury; caution with poor circulation, Raynaud phenomenon or impaired sensation.
- Cancer control: Not studied.
What was studied
CryoPac was a randomized, open-label trial of frozen gloves and socks during paclitaxel or docetaxel treatment. It randomized 268 adults; 217 were included in the modified intention-to-treat analysis (123 cryotherapy, 94 usual care). The primary endpoint was chemotherapy-induced peripheral neuropathy defined by a Total Neuropathy Score of at least 2.
The trial is registered as NCT05928429 and was published online October 6, 2026. It was found within this run’s overlapping surveillance window.
What the results show
The primary outcome occurred in 74% of the cryotherapy group and 84% of usual care (P=.071), which did not meet conventional statistical significance. Some secondary sensory symptoms and tactile measures favored cryotherapy, but there was no significant difference in CTCAE grade 2 or worse neuropathy (P=.20), global EORTC QLQ-C30 quality of life, or taxane dose modification.
Only 67% complied with the cooling protocol. The negative primary endpoint remains the central result; positive secondary measures should not be described as proof that frozen gloves and socks prevent clinically important neuropathy.
Limits and uncertainty
Open-label delivery and incomplete adherence complicate interpretation. Modified intention-to-treat denominators differed from the 268 randomized population. Multiple secondary outcomes increase false-positive risk. Results apply to the tested devices, timing and taxane regimens, not to every cooling product or compression method. Funding and conflict details not available in the PubMed abstract were not independently verified.
Safety and practical context
Cold exposure can cause pain, numbness, skin injury and, rarely, frostbite. Extra caution is required with Raynaud phenomenon, cryoglobulinemia, peripheral vascular disease, diabetes-related sensory loss, existing neuropathy or damaged skin. Cooling should follow an oncology-center protocol with frequent skin and comfort checks; never improvise with uncontrolled freezing temperatures. New neuropathy still requires prompt dose and safety review.
Questions for the care team
- Does the infusion center offer a controlled protocol and monitor skin temperature and circulation?
- Do circulation problems, existing numbness or cold-related disorders make cooling unsafe?
- How will neuropathy be assessed before each cycle, independent of whether cooling is used?
Sources checked
- CryoPac randomized trial (PMID 42838271; DOI 10.1016/j.annonc.2026.09.014)
- Trial registration NCT05928429
- Earlier systematic review of cryotherapy/compression (PMID 38955817)
Last literature search: October 18, 2026 · Record appraisal: October 18, 2026
Educational evidence summary, not personal medical advice. This record concerns symptom or supportive care. It does not establish tumor shrinkage, recurrence prevention or longer survival, and it should not delay or replace oncology treatment.
